No need for financial disclosure at Avastin hearing, officer says

06/20/2011 | San Francisco Chronicle

Karen Midthun, who will preside over a public hearing on Genentech's cancer drug Avastin next week, rejected an FDA proposal that would require witnesses to disclose financial relationships with the drug’s maker or competitors. Roche, Genentech's parent, is appealing the agency's plan to revoke Avastin's approval for breast cancer. The FDA may cross-examine witnesses if it "is concerned that there are additional financial interests that affect the credibility of the opinions advanced by the Genentech presenters," Midthun said.

View Full Article in:

San Francisco Chronicle

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Teaching Associate (Hospitality Management)
University of Illinois at Urbana-Champaign
Urbana, IL
Director, Global Regulatory Affairs
Rodan and Fields, LLC
San Francisco, CA